Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
H5N1 neuraminidase is a critical surface enzyme of the Highly Pathogenic Avian Influenza A (H5N1) virus, belonging to the glycosyl hydrolase family 34 (UniProt: P0C6Y6). Its primary biological role is to catalyze the hydrolysis of terminal sialic acid residues from host cell receptors and viral glycoproteins, a process essential for the release of newly formed virions from the host cell membrane and preventing viral aggregation. By facilitating viral spread throughout the respiratory tract and aiding in the penetration of the mucus layer, it plays a central role in the pathogenesis of avian influenza (NIH: NBK11771). This enzyme is the primary target for the neuraminidase inhibitor (NAI) class of antiviral drugs, including oseltamivir and zanamivir, which competitively bind to the conserved active site to arrest viral replication (StatPearls: NBK539909). However, the clinical utility of these drugs is threatened by the emergence of specific amino acid substitutions, such as the H274Y mutation, which significantly reduce drug sensitivity and complicate pandemic preparedness efforts. Understanding the structural dynamics of this protein is vital for the development of next-generation antivirals that can overcome existing resistance mechanisms.
Neuraminidase inhibitors competitively bind to the enzyme's highly conserved active site, preventing the cleavage of terminal sialic acid residues on host cell receptors and viral glycoproteins, which traps progeny virions on the cell surface and halts the spread of infection.
3 more in the full profile.
Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neuraminidase (Influenza A virus subtype H5N1) (NA).